Are Predictions from the Options Market Indicating a Surge in Avantor Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: NASDAQ.COM
Avantor Stock and Options Market: Investors should monitor Avantor, Inc. (AVTR) as the options market indicates high implied volatility, particularly for the Jan 16, 2026 $2.50 Put, suggesting expectations of significant price movement.
Analyst Sentiment: Avantor currently holds a Zacks Rank #4 (Sell) in the Medical Services industry, with no analysts increasing earnings estimates recently, leading to a decrease in the consensus estimate from 26 cents to 21 cents per share.
Options Trading Strategy: The high implied volatility may signal a trading opportunity, as seasoned options traders often seek to sell premium on such options, hoping the stock does not move as much as anticipated by expiration.
Quantum Computing Developments: Quantum computing is rapidly advancing, with major tech companies like Microsoft and Google integrating it into their infrastructure, and investment strategist Kevin Cook identifies stocks that could lead in this emerging field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
2 Buy
9 Hold
2 Sell
Hold
Current: 10.810
Low
8.00
Averages
12.30
High
17.00
Current: 10.810
Low
8.00
Averages
12.30
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avantor Executives Under Investigation for Breach of Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether Avantor, Inc. executives breached their fiduciary duties to shareholders, with allegations that could impact corporate governance and shareholder confidence.
- False Competitive Positioning: A federal securities lawsuit claims insiders at Avantor failed to disclose that the company's competitive positioning was weaker than publicly represented, potentially leading to investor misjudgment regarding the company's prospects.
- Negative Competitive Pressures: Avantor is reportedly experiencing adverse effects from increased competition, and the failure to disclose this information may result in shareholder losses in investment decisions, affecting the company's stock performance.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing the importance of participation, which could influence future shareholder litigation and corporate governance structures.
Continue Reading
Avantor (AVTR) Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Schedule: Avantor will release its Q4 and full-year 2025 financial results before the market opens on February 11, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: A conference call will take place on the same day at 8:00 a.m. Eastern Standard Time, aimed at providing in-depth discussions of the financial results to bolster market confidence.
- Webcast Availability: The session will be available via live audio webcast on Avantor's investor section, with a replay accessible for 30 days, ensuring that investors unable to attend live can still receive the information.
- Global Customer Base: Avantor serves over 300,000 customer locations in 180 countries, highlighting its leadership position in the life sciences and advanced technology sectors.
Continue Reading